Rachlin Evan Lockwood's Form 4 filing
Iambic Therapeutics, Inc.IAM · filed Oct 19, 2026
- Accession no.
- 0002151678-26-000007
- Filed
- Oct 19, 2026, 7:47 PM ET
- Trade date
- Oct 16, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market purchases total $11.5M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rachlin Evan LockwoodCIK 0002151678 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Common Stock | CConversionAcquired | +1,458,736 | –F1,F2 | – | 1,458,736 | Indirect | |
| Oct 16, 2026 | Common Stock | CConversionAcquired | +410,762 | –F4 | – | 1,869,498 | Indirect | |
| Oct 16, 2026 | Common Stock | PPurchaseAcquired | +718,750 | $16.00 | +$11,500,000 | 2,588,248 | Indirect | |
| Oct 16, 2026 | Common Stock | CConversionAcquired | +57,754 | –F1 | – | 57,754 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Common Stock | CConversionDisposed | −1,152,025 | $0.00 | $0 | 0 | Indirect | |
| Oct 16, 2026 | Common Stock | CConversionDisposed | −57,754 | $0.00 | $0 | 0 | Indirect | |
| Oct 16, 2026 | Common Stock | CConversionDisposed | −306,711 | $0.00 | $0 | 0 | Indirect | |
| Oct 16, 2026 | Common Stock | CConversionDisposed | −410,762 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Referenced by the price of 2 transactions in Table I.
- F2
Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Referenced by the price of 1 transaction in Table I.
- F4
The conversion price was equal to 85% of the Issuer's initial public offering price of $16.00 per share (reflecting a 15% discount).
Referenced by the price of 1 transaction in Table I.